Gilead Sciences $10 billion notes offering

Overview:

• Gilead Sciences, a bio-pharmaceutical company, offered $10 billion of notes. 
• This included the offer of $1 billion 1.85% senior notes due 2018, $2 billion 2.55% senior notes due 2020, $1 billion 3.25% senior notes due 2022, $2.75 billion 3.65% senior notes due 2026, $1 billion 4.6% senior notes due 2035 and $2.25 billion 4.75% senior notes due 2046.
• Merrill Lynch Pierce Fenner & Smith and JP Morgan Securities acted as lead joint book-running managers.

Rani Mehta - Journalist